

Multiple Myeloma Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: _____

ICD-10 Code: _____

Biomarkers/Characteristics: (select all that apply)

Transplant Candidate: __No __Yes

First Line of Therapy (1st Line)

- New Diagnosis
 - Transplant Candidates
 - VRD/VDR:** bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone
 - D-VTd:** daratumumab (Darzalex), bortezomib (Velcade), thalidomide, and dexamethasone
 - D-VRd:** daratumumab (Darzalex), bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone
 - Non-Transplant Candidates
 - CyBorD or VDC:** bortezomib (Velcade), cyclophosphamide, and dexamethasone
 - DRd:** daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone
 - R-dex:** lenalidomide (Revlimid) and low-dose dexamethasone
 - VRD/VDR:** bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone
 - Isatuximab-VRd:** bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone with isatuximab (Sarclisa)
 - VD:** bortezomib (Velcade) and dexamethasone

Second or Third Lines of Therapy (2nd or 3rd Line)

- Early Relapsed Disease
 - CRd or KRd:** carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone
 - DRD:** daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone
 - DVD:** daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone
 - PVd:** pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone*

Maintenance Therapy

- Post-Transplant, Standard Risk
 - Lenalidomide (Revlimid)**

* Eligible only if patient has received prior therapy with lenalidomide and proteasome inhibitor

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631

Last review: 8/27/2024 | Effective date: 11/4/2024

© 2024 Carelon Medical Benefits Management